A phase 1, open-label safety and immunogenicity study of an AS03-adjuvanted trivalent inactivated influenza vaccine in children aged 6 to 35 months

Background: There is a need for better vaccines and vaccine strategies to reduce the burden of influenza in very young children.   Methods: This phase 1, open-label study assessed the reactogenicity, safety, and immunogenicity of an inactivated trivalent influenza vaccine (TIV) containing low doses...

Descripción completa

Detalles Bibliográficos
Autores principales: Carmona Martinez, Alfonso, Salamanca de la Cueva, Ignacio, Boutet, Philippe, Vanden Abeele, Carline, Smolenov, Igor, Devaster, Jeanne-Marie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2014
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4186022/
https://www.ncbi.nlm.nih.gov/pubmed/25424805
http://dx.doi.org/10.4161/hv.28743

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4186022/
https://www.ncbi.nlm.nih.gov/pubmed/25424805
http://dx.doi.org/10.4161/hv.28743

Ejemplares similares